We found a reduction in CHK1 and an increase in γH2AX following adavosertib therapy, which was consistent with two earlier investigations using breast cancer, pancreatic, and osteosarcoma cell lines (34, 35). This evidence concerns the gene CHEK1 and breast cancer.